Psychoneuroendocrinology · 2011
Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: a longitudinal study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hinkelmann Kim, Moritz Steffen, Botzenhardt Johannes, Muhtz Christoph, Wiedemann Klaus, Kellner Michael, Otte Christian
Аннотация
OBJECTIVES: We have previously reported that cognitive deficits are cross-sectionally associated with elevated cortisol in depressed patients. Here, we longitudinally examined if changes in cortisol secretion during treatment are associated with improvement of cognition.
METHODS: Cognitive function and salivary cortisol levels were longitudinally examined in 52 patients with major depression before and after 3 weeks of standardized selective serotonin reuptake inhibitor (SSRI) and an add-on treatment modulating the mineralocorticoid receptor and compared to a healthy control group (n=50) matched for age, gender and years of education.
RESULTS: Across add-on treatment groups, SSRI treatment reduced salivary cortisol in patients to levels of healthy controls (time×group interaction p=.05). In patients, reduction of cortisol significantly correlated with improvement in depressive symptoms (r=.52, p<.01), speed of information processing (r=.50, p<.01), and cognitive set-shifting (r=.34, p=.03). Improved depressive symptoms were only associated with improved attention and working memory.
CONCLUSIONS: Improvement of some cognitive domains during SSRI treatment was associated with decreasing cortisol secretion and was only to a lesser extent associated with improved depressive symptoms.
METHODS: Cognitive function and salivary cortisol levels were longitudinally examined in 52 patients with major depression before and after 3 weeks of standardized selective serotonin reuptake inhibitor (SSRI) and an add-on treatment modulating the mineralocorticoid receptor and compared to a healthy control group (n=50) matched for age, gender and years of education.
RESULTS: Across add-on treatment groups, SSRI treatment reduced salivary cortisol in patients to levels of healthy controls (time×group interaction p=.05). In patients, reduction of cortisol significantly correlated with improvement in depressive symptoms (r=.52, p<.01), speed of information processing (r=.50, p<.01), and cognitive set-shifting (r=.34, p=.03). Improved depressive symptoms were only associated with improved attention and working memory.
CONCLUSIONS: Improvement of some cognitive domains during SSRI treatment was associated with decreasing cortisol secretion and was only to a lesser extent associated with improved depressive symptoms.
Предметные рубрики MeSH
AdultAntidepressive AgentsAttentionCognitionMajor Depressive DisorderDrug Therapy, CombinationFemaleFludrocortisoneHumansHydrocortisoneLongitudinal StudiesMaleMemory, Short-TermMiddle AgedMineralocorticoid Receptor AntagonistsNeuropsychological TestsPsychiatric Status Rating ScalesRandomized Controlled Trials as TopicSalivaSelective Serotonin Reuptake InhibitorsSpironolactoneYoung Adult